Quick Answer
Hyaluronic Acid Skin Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: In accordance with EMA Committee for Advanced Therapies (EMA-CAT) recommendations (Guideline on Human Cell-Based Medicinal Products, 2015, section 2.2.4a), this approach qualifies as a “technique, since the processing does not alter the biological characteristics, physiological functions, or structural properties of the cells.
Key Takeaways
- 01In accordance with EMA Committee for Advanced Therapies (EMA-CAT) recommendations (Guideline on Human Cell-Based Medicinal Products, 2015, section 2.2.4a), this approach qualifies as a “technique, since the processing does not alter the biological characteristics, physiological functions, or structural properties of the cells. [Gentile Pietro (2026)]
- 0220 patients with mild to moderate dermal thinning, reduced elasticity, and wrinkles were assigned to the study group (SG) and treated with Am-FBs (A–C). [Gentile Pietro (2026)]
- 03The Risk Evaluation and Mitigation Strategies (REMSs) incorporating Elements to Assure Safe Use (ETASU) were applied in Am-FBs and HA-based skin booster treatments, significantly reducing safety-related risks. [Gentile Pietro (2026)]
- 04, , , The natural aging process leads to the degradation of the dermal extracellular matrix (ECM), decreased fibroblast activity, and a loss of skin elasticity.Traditional cosmetic procedures, such as hyaluronic acid (HA)-based skin boosters, provide temporary benefits, but autologous cell-based therapies offer a biologically driven regenerative approach. [Gentile Pietro (2026)]
The current Migaku evidence database contains 3 reusable source documents for Hyaluronic Acid Skin Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation.
- In accordance with EMA Committee for Advanced Therapies (EMA-CAT) recommendations (Guideline on Human Cell-Based Medicinal Products, 2015, section 2.2.4a), this approach qualifies as a “technique, since the processing does not alter the biological characteristics, physiological functions, or structural properties of the cells. [Gentile Pietro (2026); evidence level 2]
- 20 patients with mild to moderate dermal thinning, reduced elasticity, and wrinkles were assigned to the study group (SG) and treated with Am-FBs (A–C). [Gentile Pietro (2026); evidence level 2]
- The Risk Evaluation and Mitigation Strategies (REMSs) incorporating Elements to Assure Safe Use (ETASU) were applied in Am-FBs and HA-based skin booster treatments, significantly reducing safety-related risks. [Gentile Pietro (2026); evidence level 2]
- , , , The natural aging process leads to the degradation of the dermal extracellular matrix (ECM), decreased fibroblast activity, and a loss of skin elasticity.Traditional cosmetic procedures, such as hyaluronic acid (HA)-based skin boosters, provide temporary benefits, but autologous cell-based therapies offer a biologically driven regenerative approach. [Gentile Pietro (2026); evidence level 2]
- Some evidence also suggests that PAE may be related to stratum corneum impairment and insufficient skin hydration []. [Zhang Di (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Autologous fibroblast therapy for facial rejuvenation: A randomized open-label controlled study
- Efficacy and Safety of Non‐Cross‐Linked Hyaluronic Acid Mesotherapy for Post‐Acne Erythema: A Split‐Face, Prospective, Randomized, Single‐Center Trial
- Combined Use of Botulinum Toxin A and Profhilo for Upper Face Rejuvenation: A Randomized Clinical Trial.